Shareholder Group Again Attacks Pharmacopeia, Eos Acquisition | GenomeWeb

SAN FRANCISCO, Jan. 8 – In its latest attempt to kill Pharmacopeia's acquisition of Eos Biotechnology, OrbiMed Advisors, a financial services firm that owns the greatest single stake in Pharmacopeia stock, on Tuesday urged shareholders to follow its lead and vote against the proposed deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."